Mark Cook

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

María‐Victoria Mateos, Meletios Α. Dimopoulos, Michèle Cavo et al. · New England Journal of Medicine · 2017 · 984 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Paula Rodríguez‐Otero, Sikander Ailawadhi, Bertrand Arnulf et al. · New England Journal of Medicine · 2023 · 705 citations · Full text

Medicine, Immunology, Oncology +17

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Michèle Cavo, Joan Bladé et al. · The Lancet · 2019 · 438 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)

Oliver Goodyear, Mike Dennis, Nadira Jilani et al. · Blood · 2012 · 398 citations

Life Sciences, Immunology, Oncology +17

Efficient Removal of Immunoglobulin Free Light Chains by Hemodialysis for Multiple Myeloma

Colin A. Hutchison, Paul Cockwell, Steven D. Reid et al. · Journal of the American Society of Nephrology · 2007 · 268 citations

Medicine, Hematology, Nephrology +10